175 related articles for article (PubMed ID: 35990738)
1. Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system.
Belloni D; Ferrarini M; Ferrero E; Guzzeloni V; Barbaglio F; Ghia P; Scielzo C
STAR Protoc; 2022 Sep; 3(3):101601. PubMed ID: 35990738
[TBL] [Abstract][Full Text] [Related]
2. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
3. Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy.
Ferrarini M; Steimberg N; Ponzoni M; Belloni D; Berenzi A; Girlanda S; Caligaris-Cappio F; Mazzoleni G; Ferrero E
PLoS One; 2013; 8(8):e71613. PubMed ID: 23990965
[TBL] [Abstract][Full Text] [Related]
4. 3D-Dynamic Culture Models of Multiple Myeloma.
Ferrarini M; Steimberg N; Boniotti J; Berenzi A; Belloni D; Mazzoleni G; Ferrero E
Methods Mol Biol; 2017; 1612():177-190. PubMed ID: 28634943
[TBL] [Abstract][Full Text] [Related]
5. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
Kikuchi J; Koyama D; Mukai HY; Furukawa Y
Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents.
Barbaglio F; Belloni D; Scarfò L; Sbrana FV; Ponzoni M; Bongiovanni L; Pavesi L; Zambroni D; Stamatopoulos K; Caiolfa VR; Ferrero E; Ghia P; Scielzo C
Haematologica; 2021 Sep; 106(9):2334-2344. PubMed ID: 32732361
[TBL] [Abstract][Full Text] [Related]
7. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma.
Faid L; Van Riet I; De Waele M; Facon T; Schots R; Lacor P; Van Camp B
Eur J Haematol; 1996 Nov; 57(5):349-58. PubMed ID: 9003475
[TBL] [Abstract][Full Text] [Related]
8. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.
de la Puente P; Muz B; Gilson RC; Azab F; Luderer M; King J; Achilefu S; Vij R; Azab AK
Biomaterials; 2015 Dec; 73():70-84. PubMed ID: 26402156
[TBL] [Abstract][Full Text] [Related]
9. Air-liquid organotypic assays to investigate cellular crosstalk in the tumor microenvironment of cancer cells.
Cid-Diaz T; Lodeiro AC; Duran A; Moscat J; Diaz-Meco MT
STAR Protoc; 2022 Sep; 3(3):101635. PubMed ID: 36035805
[TBL] [Abstract][Full Text] [Related]
10. Chronic B cell malignancies and bone marrow microenvironment.
Ghia P; Granziero L; Chilosi M; Caligaris-Cappio F
Semin Cancer Biol; 2002 Apr; 12(2):149-55. PubMed ID: 12027587
[TBL] [Abstract][Full Text] [Related]
11. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.
Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J
Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.
Gao L; Li B; Yang G; Liu P; Lan X; Chang S; Tao Y; Xu Z; Xie B; Sun X; Wang Y; Hu L; Yu D; Xie Y; Bu W; Wu X; Zhu W; Shi J
Cancer Lett; 2018 May; 421():135-144. PubMed ID: 29428642
[TBL] [Abstract][Full Text] [Related]
13. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
Wang X; Li C; Ju S; Wang Y; Wang H; Zhong R
Leuk Lymphoma; 2011 Oct; 52(10):1991-8. PubMed ID: 21718132
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
Alonso S; Hernandez D; Chang YT; Gocke CB; McCray M; Varadhan R; Matsui WH; Jones RJ; Ghiaur G
J Clin Invest; 2016 Dec; 126(12):4460-4468. PubMed ID: 27775549
[TBL] [Abstract][Full Text] [Related]
15. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
[TBL] [Abstract][Full Text] [Related]
16. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
17. Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes.
Ganan-Gomez I; Clise-Dwyer K; Colla S
STAR Protoc; 2022 Dec; 3(4):101764. PubMed ID: 36240061
[TBL] [Abstract][Full Text] [Related]
18. A comparison of cytokine production in 2-dimensional and 3-dimensional cultures of bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.
Zdzisińska B; Roliński J; Piersiak T; Kandefer-Szerszeń M
Folia Histochem Cytobiol; 2009; 47(1):69-74. PubMed ID: 19419941
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells.
Huang N; Kawano MM; Mahmoud MS; Mihara K; Tsujimoto T; Niwa O; Kuramoto A
Blood; 1995 Jun; 85(12):3704-12. PubMed ID: 7780154
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
Bar-Natan M; Stroopinsky D; Luptakova K; Coll MD; Apel A; Rajabi H; Pyzer AR; Palmer K; Reagan MR; Nahas MR; Karp Leaf R; Jain S; Arnason J; Ghobrial IM; Anderson KC; Kufe D; Rosenblatt J; Avigan D
Br J Haematol; 2017 Mar; 176(6):929-938. PubMed ID: 28107546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
